Tailoring Omega-3 Dosing by Genotype May Help Prevent Early Preterm Birth
This study takes a second look at data from the ADORE trial, a large study that gave pregnant women different doses of DHA (a key omega-3 fatty acid) to see how it affected pregnancy length. Researchers focused on a specific gene variant called the FADS Indel, which affects how efficiently a person’s body converts and uses omega-3 fats.
The analysis explored whether matching a woman’s DHA dose to her FADS genotype could help reduce the risk of spontaneous early preterm birth and also prevent pregnancies from going too far past their due date (prolonged gestation). The idea is that people with certain gene variants may need more or less DHA to get the same metabolic benefit.
By examining outcomes through this genetic lens, the researchers aimed to understand whether a one-size-fits-all DHA dose is less effective than a personalized approach based on genetic differences in fatty acid metabolism.
What this means for you
For pregnant individuals, this research suggests that genetic differences may influence how much benefit a person gets from omega-3 supplementation during pregnancy, and that future prenatal nutrition guidance could become more personalized. It does not establish that any specific DHA dose prevents preterm birth for everyone, and anyone considering omega-3 supplementation during pregnancy should discuss it with their healthcare provider.
Ready to start? The ALP Protocol delivers the EPA & DHA doses used in the research.
Start the ALP ProtocolThis summary is for educational purposes only and is not medical advice. Always talk to your healthcare provider before making changes to your supplement routine.